The short answer: what medical supply companies trade for in 2026

Medical supply companies in the lower middle market generally trade between 3x and 10x trailing-twelve-month adjusted EBITDA, with the range set by product category, regulatory profile, and customer concentration. Pure distributors of commodity supplies sit at the low end (3x-6x). Specialty distributors with clinical services or 510(k)-cleared devices command 6x-10x. FDA-registered manufacturers with proprietary SKUs can exceed 10x when growth and margin support it.

Two anchor points. Owens & Minor announced its $1.36 billion cash acquisition of Rotech Medical in July 2024 at a headline multiple around 8.7x pro-forma EBITDA, a home medical equipment platform (Owens & Minor investor release, July 2024). Patient Square Capital took Patterson Companies private in December 2024 at $31.35 per share, roughly $4.1 billion enterprise value, implying about 9.5x EBITDA on a diversified dental and animal-health distributor (Patterson SEC DEFA14A, December 2024).

Distributor vs manufacturer: the single biggest valuation driver

Distributor versus manufacturer is the largest single lever in medical supply valuation, often worth 3-5 turns of EBITDA. Distributors resell third-party products at 15%-30% gross margins with low technical moats. Manufacturers own the product, control the specification, and defend margin through 510(k) clearances or ISO 13485 quality systems. Buyers pay for defensibility, and defensibility lives with the manufacturer.

Why distributors sit at 3x-6x

Distribution economics are volume driven. Gross margin sits in the mid-teens for national broadline distributors (Cardinal Health reported medical segment gross margin near 4.4% in Q2 FY2025 per its SEC filings) and 20%-30% for specialty regional distributors. Switching costs for hospital customers are moderate: a competing distributor can service the same GPO contract inside 90 days. Working capital is heavy, inventory turns hover between 6x and 10x per year for broadline players, and pricing power sits with the manufacturer above and the group purchasing organization below.

Why manufacturers stretch to 8x-12x+

A 510(k)-cleared or PMA-approved device carries pricing power that survives a distributor swap. Manufacturers with 40%+ gross margins, an installed base, and consumable pull-through routinely clear 10x EBITDA when growth is 15%+ and customer concentration is under 15%. ResMed, Inspire Medical Systems, and Insulet all trade at manufacturer multiples that exceed 20x EBITDA in public markets (ResMed investor page), which cascades down into private LMM deals as buyer expectations for premium assets.

Lower-middle-market multiple table (2026)

The table below reflects transactions we track between $5M and $75M enterprise value in medical supply and durable medical equipment (DME). Ranges assume clean quality of earnings, single-digit customer concentration, and no open FDA warning letters. Deviate on any of those variables and the multiple compresses.

Public strategics like Cardinal Health, Owens & Minor, McKesson, Henry Schein, and Patterson set the ceiling. When Patterson traded at roughly 9.5x, LMM distributor sellers benchmarking above 6.5x had to justify why they deserved a premium relative to a public diversified distributor.

How to normalize EBITDA before applying a multiple

Normalized EBITDA in medical supply valuation typically differs from reported EBITDA by 10%-25%. Owners who skip this step often anchor to a multiple that a buyer will not underwrite. A quality of earnings (QoE) report converts reported net income into an EBITDA figure a lender and a buyer will both accept.

1. Owner compensation. Adjust to a market-rate CEO or general manager salary. In 2026, a $30M-revenue medical distributor typically supports $250K-$400K in total comp per BLS OES data for chief executives. Excess comp is an add-back.
2. Related-party rent. Reset any owner-occupied real estate to fair market lease rates. CoStar and CBRE regional data can back the number.
3. Personal expenses. Auto leases, discretionary travel, non-business insurance, and family payroll get removed with clean documentation.
4. Inventory obsolescence reserve. This is the medical-specific killer. See the dedicated section below.
5. Non-recurring items. COVID-era PPE sales that will not repeat, one-time legal, a settled workers comp claim.
6. Run-rate customer wins or losses. Contracted business added or lost inside the trailing 12 months, normalized to annual.

For a full sell-side view of how buyers scrutinize these numbers, our Quality of Earnings report deep dive walks through the specific schedules a QoE provider will build.

Customer concentration: the hidden multiple compressor

Customer concentration in medical supply valuation is the single most common reason a purchase price gets cut between LOI and close. Buyers underwrite the loss of the top customer. When one hospital system or one GPO represents more than 20% of revenue, buyers apply a discount, structure earnouts, or walk. The math is not opinion: it protects the buyer against a real 12-24 month risk after change of control.

GPO contracts sit inside customer concentration

Vizient, Premier, and HealthTrust represent roughly 90% of US hospital purchasing volume per Healthcare Supply Chain Association data. A distributor with strong Vizient or Premier tier-one contract status has real pull-through, but the contract itself typically has a 60-90 day termination clause. Buyers price the contingent nature. A copy of every GPO agreement, with award tier and expiration date, belongs in the data room from day one.

Regulatory posture: FDA, DSCSA, and ISO 13485

Regulatory readiness in medical supply valuation moved from a diligence checkbox to a top-three price driver between 2023 and 2026. Distributors face the Drug Supply Chain Security Act (DSCSA) enhanced traceability rules that the FDA fully enforced starting November 27, 2024 for large trading partners after a stabilization period (FDA DSCSA enforcement page). Manufacturers face FDA 21 CFR Part 820 quality system regulation and, since February 2026, harmonization with ISO 13485:2016 under the Quality Management System Regulation (QMSR) final rule.

What buyers actually check

• FDA Form 483 observations from the past 5 years, and any Warning Letters
• DSCSA serialization readiness at the SGTIN, SSCC, and EPCIS event level
• Vendor and lot traceability records for a random sample of 25 SKUs
• ISO 13485 certification with active surveillance audits, or QMSR compliance documentation for post-February 2026 manufacturers
• State-level medical device distributor licenses (California, Florida, Texas each have their own regime)
• DEA registration if any Schedule II-V products move through the warehouse
• Medicare DME PTAN and accreditation from BOC, ABC, or ACHC for HME sellers

An open FDA Warning Letter can compress a multiple by 1-3 turns or trigger a walk. A CAPA-in-progress with documented remediation is usually manageable. Owners preparing for exit should close open observations at least 12 months before going to market.

Inventory quality: the diligence line that resets EBITDA

Inventory quality often resets medical supply EBITDA by 5%-15% in diligence. Buyers do not accept the balance sheet number at face value. They run three tests: weeks of coverage (WOC), obsolescence reserve adequacy, and expiration dating on sterile SKUs. Any one of the three can trigger a purchase price adjustment.

1. Weeks of coverage. Divide on-hand inventory by average weekly cost of goods sold. Broadline distribution should sit at 5-10 weeks. Specialty at 8-14. Anything above 20 weeks signals dead stock.
2. Obsolescence reserve. A reserve under 3% of gross inventory in a medical distributor is usually inadequate. Buyers rebuild the reserve using SKU-level velocity and dating data. That rebuild flows through cost of goods sold and cuts EBITDA.
3. Expiration dating. Sterile SKUs, reagents, and pharmaceuticals must show remaining shelf life. Anything under 6 months to expiration usually gets written to zero.
4. Consigned inventory. Product sitting in hospital cabinets on consignment gets separately verified. Missing consignment reconciliations are a red flag.

A worked example. A $6M inventory book with 3% reserved reserve, $180K. Buyer diligence finds 8% of SKUs are within 6 months of expiration and 4% are dead stock over 18 months old. Adjusted reserve at 9%, $540K. The $360K delta hits COGS and can drop EBITDA by the same amount, worth $2M-$3M in purchase price at a 6x-8x multiple. Owners who audit their own inventory 90 days before marketing avoid this outcome.

Buyer types: who pays what for a medical supply company

Buyer type shapes both valuation and deal structure in medical supply. The same asset can command different prices from a strategic acquirer, a PE platform, a family office, or a search fund. Sellers who understand the buyer universe run a competitive process and capture the top of the range. Our strategic buyer vs financial buyer guide covers the broader trade-offs.

Strategic buyers

Cardinal Health, McKesson, Owens & Minor, Henry Schein, Patterson, and mid-market strategics like AdaptHealth typically pay for synergies. They can absorb overhead, cross-sell into an existing customer base, and consolidate warehouses. Strategics tend to pay 0.5-1.5 turns above financial buyers for platform-fit assets but underwrite hard on integration risk.

Private equity platforms

Financial sponsors like New Mountain Capital (invested in Real Chemistry and adjacent healthcare services), Court Square, and lower-mid-market firms like MidOcean, Riverside, and Nautic fund buy-and-build platforms in medical distribution. They pay platform multiples of 8x-11x for the first acquisition and tuck-in multiples of 4x-6x thereafter. Add-on economics are the reason a $15M EBITDA specialty distributor can attract 9x from a sponsor even when public comps trade lower.

Family offices and independent sponsors

Family offices often pay closer to strategic multiples for durable, defensible businesses without demanding a five-year exit. Independent sponsors carry deal-by-deal capital and may need seller financing or rollover to close.

Search funds and self-funded searchers

Searchers target $1M-$5M EBITDA companies, usually at 3x-5x. Medical supply distribution with recurring revenue and a licensable customer base is a common target. Sellers who accept a search fund buyer often trade multiple for management continuity and legacy protection.

Recent named comparable transactions (2024-2026)

Named comparables anchor a valuation conversation better than any generic multiple range. The transactions below are public-record deals in medical supply, distribution, and related healthcare consumables. Sellers should build their own transaction comp book with 8-12 relevant deals before going to market.

Sources: Owens & Minor investor relations, SEC EDGAR, Cardinal Health newsroom, and McKesson news.

Working capital peg and net debt: what actually flows to the seller

Enterprise value is not what the seller nets. Two mechanics decide the cash-at-close number: the net working capital (NWC) peg and the net debt calculation. In medical supply, both are contentious because inventory sits inside NWC and vendor rebate accruals live in a gray zone.

1. NWC peg. Buyers set the peg at a trailing 12-month average of accounts receivable plus inventory minus accounts payable and accrued expenses. Sellers should benchmark and negotiate the peg 90 days before signing.
2. Excess inventory. Any inventory above the peg on the closing balance sheet does not typically get paid for at cost. Rebuild the working capital target with actual seasonality data.
3. Vendor rebates. Manufacturer volume rebates accrue but often collect on lag. Buyers negotiate whether accrued rebates are seller assets or transfer to buyer.
4. Deferred revenue and customer deposits. Treated as debt-like items by most buyers.
5. Chargebacks and returns reserve. Sterile products, expired product returns, and hospital chargebacks all sit here.

A $50M enterprise value deal with a poorly modeled NWC peg can leave $2M-$4M on the table. This is one of the highest-ROI conversations to have before signing an LOI.

The valuation math: worked example

A worked example shows how the factors above combine into a defensible number. Consider a specialty wound care distributor with $28M revenue, $4.5M reported EBITDA, one hospital system at 22% of revenue, ISO 13485 not applicable, DSCSA compliant, no FDA issues.

• Reported EBITDA: $4.5M
• Owner comp add-back: +$180K
• Related-party rent adjustment: -$60K (rent was below market)
• Inventory obsolescence rebuild: -$220K
• One-time legal settlement: +$95K
• Normalized EBITDA: $4.495M, round to $4.5M
• Base multiple (specialty distribution): 6.5x
• Customer concentration adjustment: -0.5x (top customer 22%)
• Growth premium (18% YoY, three-year CAGR): +0.5x
• Applied multiple: 6.5x
• Enterprise value: $29.25M
• Less net debt: -$1.8M
• Less NWC peg adjustment: -$0.4M
• Cash at close (before escrow): ~$27M

Any structural feature (rollover equity, seller note, earnout tied to hospital contract renewal) can shift the split between cash and contingent consideration but rarely lifts the enterprise value beyond the buyer’s underwriting range.

What actually lifts the multiple: the six-lever checklist

Six specific items separate a bottom-of-range sale from a top-of-range outcome. Owners who address all six over 12-24 months of pre-sale preparation typically capture 1.5-3.0 additional turns of EBITDA. Our prepare your business for sale hub covers the broader operating playbook.

1. Diversify the top-three customer list until no single customer exceeds 15% of revenue.
2. Rebuild inventory reserves with SKU-level velocity data and clear obsolescence policies.
3. Close FDA observations and document CAPAs at least 12 months before market.
4. Renew or extend GPO contracts so the buyer inherits multi-year visibility.
5. Commission a sell-side quality of earnings from a healthcare-experienced provider.
6. Invest in a second-line management team so the deal does not depend on the founder staying five years.

Common valuation mistakes owners make

A handful of mistakes recur across medical supply sellers and cost real money at the closing table. Every one of them is preventable with sequencing and disciplined preparation.

• Anchoring to a public strategic multiple without adjusting for private-market discount and size premium
• Treating inventory at book value in an environment where 10%+ of SKUs may be effectively obsolete
• Ignoring the DSCSA compliance record and hoping the buyer skips it
• Assuming a GPO contract is transferable when the contract explicitly requires re-award
• Underestimating the working capital peg negotiation
• Waiting until after LOI to fix add-back documentation
• Running a single-buyer process when a competitive tender routinely lifts price 15%-25%

How CT Acquisitions values medical supply companies

CT Acquisitions runs sell-side processes for medical supply and DME companies between $1M and $50M in EBITDA. Our process typically starts with a two-week diagnostic that yields a defensible enterprise value range, a normalized EBITDA build, and a buyer list of 40-80 vetted strategics, PE platforms, family offices, and international acquirers. Owners can review our full M&A advisory approach or our vertical-specific M&A advisor for manufacturing businesses guide for the manufacturer end of the spectrum.

Owner-aligned fees, 100+ vetted institutional buyers, and Sheridan, Wyoming home base. If you are 12-24 months from an exit and want to know what your business is worth before you commit to a process, request a confidential valuation.

Frequently asked questions

What multiple does a medical supply company sell for?

Medical supply companies in the lower middle market usually sell between 3x and 10x adjusted EBITDA. Commodity broadline distributors sit at 3x-5x. Specialty distributors and home medical equipment at 5x-8x. Contract manufacturers and 510(k)-cleared branded manufacturers at 7x-12x or higher. Multiples above the top of range require category leadership, single-digit customer concentration, and clean regulatory history.

How do you value a medical distribution company specifically?

Value a medical distribution company by normalizing EBITDA, applying a multiple based on sub-segment (broadline vs specialty vs HME), and adjusting for customer concentration, GPO contract quality, inventory health, and DSCSA compliance. Distribution multiples typically land 2-4 turns below manufacturer multiples for the same revenue size because distributors carry lower gross margin and lower switching costs.

What is a good EBITDA margin for a medical supply distributor?

A healthy EBITDA margin for a medical supply distributor sits between 8% and 15%. Broadline distributors run 4%-7% (Cardinal Health medical segment operates near the low end). Specialty distributors run 12%-20%. Manufacturers typically post 20%-35% EBITDA margins. Margins outside these ranges either signal a differentiated model or an unsustainable pricing structure that will normalize under new ownership.

Does customer concentration always reduce the multiple?

Customer concentration above 20% almost always reduces the multiple. The exact hit depends on the customer identity, contract length, and switching cost. A five-year contracted revenue stream from a AAA-rated hospital system attracts less discount than a purchase-order relationship with a regional clinic. Sellers can offset some concentration risk with rollover equity, seller notes, and structured earnouts tied to retention.

How long does DSCSA compliance take to prove in diligence?

DSCSA compliance diligence typically takes 3-6 weeks. Buyers request SGTIN and EPCIS event logs, verify trading partner authorization records, and sample 25-50 SKUs across suppliers. Distributors that stood up serialization workflows before the FDA’s November 2024 enforcement date usually pass. Distributors still working with paper T3s or ad-hoc processes should expect diligence to extend the timeline and, in some cases, compress the multiple.

Do strategic buyers or PE buyers pay more for medical supply companies?

Strategic buyers usually pay 0.5-1.5 turns more than PE for platform-fit assets because they can extract synergies. PE pays platform multiples of 8x-11x for the first buy in a sub-segment and lower tuck-in multiples afterward. Strategic buyers underwrite integration risk more conservatively, so the highest headline offer sometimes comes with tighter reps and warranties, longer indemnity periods, or larger escrows.

What is the FDA QMSR and does it change valuation?

The FDA Quality Management System Regulation (QMSR) took effect February 2, 2026, replacing 21 CFR Part 820 and harmonizing US quality system requirements with ISO 13485:2016. For medical device manufacturers, an active ISO 13485 certificate maps closely to QMSR compliance and materially reduces buyer diligence friction. Non-certified manufacturers should expect deeper quality system diligence, and in some cases, a purchase price holdback pending certification.

How much does a professional business valuation cost for a medical supply company?

A defensible sell-side valuation and quality of earnings package for a medical supply company typically costs $25K-$85K depending on revenue size, entity complexity, and multi-state operations. That fee is usually 15-40x paid back in a competitive sale process through better negotiation use and reduced re-trade risk after LOI. Owners can review typical M&A advisor fees for the full process view.